IPP Bureau
G42 Healthcare, Abu Dhabi and AstraZeneca to collaborate on clinical research
By IPP Bureau - December 29, 2021
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
By IPP Bureau - December 28, 2021
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
RaphaCure partners with Zeebon for foraying into North East market
By IPP Bureau - December 28, 2021
Zeebon is the largest diagnostics services provider in North-Eastern states
Granules Inc., receives ANDA approval for prazosin hydrochloride
By IPP Bureau - December 28, 2021
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
Trastuzumab deruxtecan type II variation application validated by EMA
By IPP Bureau - December 28, 2021
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Cipla receives EUA for Cipmolnu
By IPP Bureau - December 28, 2021
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Sun Pharma receives DCGI approval for Molxvir in India
By IPP Bureau - December 28, 2021
The product is expected to be available in a week’s time
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
By IPP Bureau - December 28, 2021
It plans to deliver over 300 million doses to the Indian government
NATCO receives approval for the drug for the treatment of Covid-19
By IPP Bureau - December 28, 2021
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Torrent Pharma to launch molnupiravir under the brand name Molnutor in India
By IPP Bureau - December 28, 2021
DCGI approved the drug based on the review of clinical data
Strides to market molnupiravir under the brand name Stripiravir
By IPP Bureau - December 28, 2021
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
By IPP Bureau - December 28, 2021
The company will market it under the brand name Molflu
Aurobindo to manufacture and market molnupiravir
By IPP Bureau - December 28, 2021
The drug will be marketed under the brand name Molnaflu
Optimus Pharma to manufacture and market molnupiravir
By IPP Bureau - December 28, 2021
The company has developed the API in house at its R&D center in Hyderabad
Covaxin receives approval for Emergency Use in Children 12-18 years
By IPP Bureau - December 27, 2021
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
